Merck & Co is to apply for a new indication for its antibiotic Zerbaxa (ceftolozane+tazobactam), after it hit target in a new clinical trial. The US-based pharma said it will apply to the Food and ...

CHMP backs Zerbaxa Merck had some more good news in the last few days after the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of its antibiotic Zerbaxa ...

Wall Street analysts forecast that Merck (MRK) will report quarterly earnings ... The consensus among analysts is that 'Sales- Hospital Acute Care- Zerbaxa' will reach $65.05 million.